{"article": [{"url": "https://www.marketwatch.com/story/immurons-stock-pulls-back-but-still-nearly-doubles-after-stock-offering-2020-07-21", "published": 1595322500.0, "headline": "Immuron's stock pulls back but still nearly doubles after stock offering", "body": "Shares of Immuron Ltd. IMRN, +5.56% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary shares. The offering to \"several healthcare-focused institutional investors, which represents about 24% of the ADS outstanding, was priced at $18.75 per ADS. That's below current premarket trading levels, but is 80% above Monday's closing price of $10.41. The stock was up 93% in premarket trading in record territory, but was up as much as 148% earlier. The company had announced earlier that its IMM-124E used to make its gastrointestinal and digestive health immune supplements Travelan and Proectyn demonstrated neutralizing activity against SARS-CoV-2, but that was in \"laboratory studies.\" The stock had run up 63.4% on Monday. It has nearly tripled (up 187%) year to date through Monday, while the iShares Nasdaq Biotechnology ETF IBB, +0.81% has rallied 21.0% and the S&P 500 SPX, +0.87% has gained 0.7%."}]}